Leena Menghaney, South Asia Head for MSF’s Access Campaign:
“If approved for use, the first oral antiviral treatment molnupiravir could be a major step forward in the provision of potentially lifesaving care for COVID-19 patients in resource-constrained settings, where billions of people remain unvaccinated and vulnerable to the disease. The drug will need to be made available and affordable as quickly as possible for people who need it everywhere. Oral drugs will be easier to use than the treatments that exist for COVID-19 so far, and allow for much broader administration, as long as they are affordable.
“While Merck is expected to charge US$700 for a five-day treatment course of molnupiravir, a new independent study by researchers at Harvard University has estimated the sustainable generic price for a treatment course to be $20. Indian generic manufacturers competing with one another are expected to launch the drug after emergency use approval in India for less than $15 per treatment course, as the drug is not yet patented in India – this is a full 46 times less than what Merck plans to charge.
“While the US government funded Emory University for the development of molnupiravir, pharmaceutical corporations Ridgeback and Merck obtained the licensing and rights for the medicine. Instead of offering broad open licenses widely to all able manufacturers in different countries, a narrow voluntary license agreed by Merck in April 2021 only includes Indian generic companies, and hinders countries like Brazil from being able to produce and import generic versions and raw materials. Middle-income countries excluded from the license had 30 million COVID-19 infections in the first half of 2021, 50% of all infections in low- and middle-income countries.
“Despite several low-cost generic versions already developed in India and in the pipeline in Bangladesh, Merck retains control in high-income and many middle-income countries because of patents, and gets to determine which countries to supply the drug to and at what price. As opposed to large protein-based biological medicines, molnupiravir is a small-molecule drug that would be simple to produce and register for generic producers around the world.
“The molnupiravir case illustrates why the ‘TRIPS Waiver’ is so urgently needed, which would waive intellectual property for COVID-19 medical tools during the pandemic and would remove legal barriers so that countries the world over could produce versions of these medicines and more lives could be saved.”
For interviews, please contact Shailly Gupta, Shailly.GUPTA@geneva.msf.org, +41 79 203 13 02